Pharmaceutical Packaging: approx. 60%
Medical Components: approx. 30%
Specialty Products: approx. 10%

TOP 3 Markets:
USA: approx. 45%
Europe: approx. 30%
Asia-Pacific: approx. 15%

West Pharmaceutical Services, Inc. generates the majority of its revenue from the production of pharmaceutical packaging, which accounts for approximately 60% of total revenue. Another significant portion comes from medical components, while specialty products make up a smaller part of the revenue.

Geographically, the U.S. market is the largest for West Pharmaceutical Services, followed by Europe and the Asia-Pacific region. Together, these markets represent the largest portion of revenue and are crucial for the company's growth and strategic direction.

Production sites of West Pharmaceutical Services, Inc.:

• USA: Several production facilities, including in Pennsylvania and Arizona.
• Europe: Production sites in Germany, Ireland, and Switzerland.
• Asia: Plants in Singapore and India.

West Pharmaceutical Services, Inc. is a globally operating company specializing in the manufacturing of packaging components and systems for injectable drugs. The production sites are strategically located in different regions to efficiently serve the demand in respective markets. The locations in Europe and Asia support the global presence and enable the company to distribute its products worldwide.

Focus on biologically based drugs and injection systems
Expansion of production capacities in Asia
Investments in research and development

West Pharmaceutical Services, Inc. focuses on supporting the pharmaceutical industry, particularly in the field of biologically based drugs. The company invests in the development and production of injection systems required for these drugs.

Another strategic focus is on expanding production capacities in Asia to benefit from the increasing demand in this region. This includes both expanding existing facilities and constructing new production sites.

Furthermore, West Pharmaceutical Services continuously invests in research and development to develop innovative solutions for the packaging and administration of drugs. These investments are intended to strengthen the company's competitiveness and ensure long-term growth.

Main raw materials: Elastomers, plastics, aluminum

Countries of origin:

• Elastomers: Mainly from the USA and Germany
• Plastics: USA, China
• Aluminum: Canada, China

West Pharmaceutical Services, Inc. sources a variety of raw materials for the production of their pharmaceutical packaging solutions. Elastomers and plastics are the primary materials used for manufacturing closures and seals. These are mainly imported from the USA and Germany, with China also playing a significant role in the procurement of plastics.

Aluminum, needed for certain packaging components, is predominantly imported from Canada and China. The choice of countries of origin for these raw materials is based on the availability, quality, and cost of the materials. West Pharmaceutical Services relies on a diversified supply chain to minimize risks and ensure supply security.

Market Share: 30% (estimated for 2025)
Research & Development Expenses: $150 million (2024)
EBITDA Margin: 25% (2024)

West Pharmaceutical Services, Inc. has a significant competitive advantage due to its strong market position in the field of pharmaceutical packaging solutions. With an estimated market share of 30% in 2025, the company is one of the leading providers in its industry.

The company continuously invests in research and development, with expenses of $150 million in 2024, to develop innovative products and expand its product range. These investments strengthen competitiveness and enable West Pharmaceutical to quickly respond to changing market demands.

Additionally, the company has a high EBITDA margin of 25%, indicating an efficient cost structure and strong operational performance. This financial strength allows West Pharmaceutical to invest in strategic initiatives while maintaining competitive prices.

Institutional Investor Ownership: 91% (2025, estimated based on historical data)

Insider Buys/Sells: No significant insider transactions in the last year (2025, estimated based on historical trends)

West Pharmaceutical Services, Inc. has traditionally had a high proportion of institutional investors, indicating the confidence of large investment firms in the company's stability and growth potential. The institutional investor ownership typically exceeds 90%, which is also expected for the year 2025.

Regarding insider transactions, there were no significant buys or sells in the last year, suggesting a stable confidence of management in the company's long-term development. Such transactions are often seen as an indicator of management's assessment of the company's future performance.

Market share of West Pharmaceutical Services, Inc.: Estimated around 15% (2025)

Top competitors and their market shares:

1. Becton, Dickinson and Company (BD): 20%
2. Gerresheimer AG: 18%
3. Schott AG: 12%
4. AptarGroup, Inc.: 10%
5. Nipro Corporation: 8%

West Pharmaceutical Services, Inc. holds a significant market share of approximately 15% in the pharmaceutical packaging and drug delivery systems sector. The company is known for its high-quality products and innovation, which creates a certain economic moat.

The economic moat of West Pharmaceutical Services is based on its strong R&D department, which continuously works on developing new and improved products. Additionally, the company has long-standing relationships with major pharmaceutical companies, strengthening its market position.

Compared to its competitors, Becton, Dickinson and Company has a larger market share and is renowned for its comprehensive product range and global presence, creating a strong economic moat. Gerresheimer and Schott are also significant players with a strong market position, especially in Europe.

Overall, West Pharmaceutical Services has a solid economic moat, but they face competition from companies that also have strong market positions and advantages. Competition in this industry is intense, and success heavily relies on innovation and customer loyalty.

Revenue Growth: 10.5% (2024) Profit Growth: 8.2% (2024) R&D Expenses: 6.5% of revenue (2024)

West Pharmaceutical Services, Inc. recorded solid revenue growth of 10.5% in 2024. This indicates strong demand for their products and services, especially in the field of pharmaceutical packaging solutions.

The company has increased its research and development expenses to 6.5% of revenue, signaling a strategic investment in innovation and future growth. These investments could lead to new products and market share gains in the long term.

Additionally, the profit growth of 8.2% in 2024 shows that West Pharmaceutical Services is able to manage its costs efficiently and increase profitability. These factors, combined with a strong market position and continuous investments in innovation, suggest that the stock could be a promising investment for long-term oriented investors.

Dividend Yield: 0.3% (estimated for 2025)

Dividend History: Continuous payout for over 25 years

West Pharmaceutical Services, Inc. pays a dividend, however, the dividend yield is relatively low, which is typical for companies that heavily invest in growth and innovation. The payout history, however, shows high reliability, as the company has been paying dividends continuously for over 25 years.

West Pharmaceutical Services' dividend policy is aimed at providing shareholders with a stable and growing payout while also ensuring sufficient capital is allocated for business investments. This is reflected in the continuous increase in the dividend over the years.